Randomized multicenter investigation of folate plus vitamin B12 supplementation inschizophrenia.

Prevention of congenital malformations and other adverse pregnancy outcomes with4.0 mg of folic acid: community-based randomized clinical trial in Italy and the Netherlands.
4 agosto 2017
J Int Soc Sports Nutr. 2015 Apr 24;12:19
4 agosto 2017

Randomized multicenter investigation of folate plus vitamin B12 supplementation inschizophrenia.

Roffman JL1, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, Silverstein NJ, Smoller JW, Hill M, Goff DC.



More effective treatments are needed for negative symptoms of schizophrenia, which are typically chronic, disabling, and costly. Negative symptoms have previously been associated with reduced blood folate levels, especially among patients with low-functioning variants in genes that regulate folate metabolism, suggesting the potential utility of folate supplementation.


To determine whether folic acid plus vitamin B12 supplementation reduces negative symptoms ofschizophrenia and whether functional variants in folate-related genes influence treatment response.


Parallel-group, randomized, double-blind, placebo-controlled clinical trial of 16 weeks of treatment with 2 mg of folic acid and 400 ฆฬg of vitamin B12.


Three community mental health centers affiliated with academic medical centers in the United States.


Outpatients with chronic schizophrenia who were psychiatrically stable but displayed persistent symptoms despite antipsychotic treatment. Eligible patients were 18 to 68 years old, were treated with an antipsychotic agent for 6 months or more at a stable dose for 6 weeks or more, and scored 60 or more on the Positive and Negative Syndrome Scale.


One hundred forty subjects were randomized to receive daily oral folic acid plus vitamin B12 or placebo.


Change in negative symptoms (Scale for the Assessment of Negative Symptoms [SANS]), as well as positive and total symptoms (Positive and Negative Syndrome Scale).


Folate plus vitamin B12 improved negative symptoms significantly compared with placebo (group difference, -0.33 change in SANS score per week; 95% CI, -0.62 to -0.05) when genotype was taken into account but not when genotype was excluded. An interaction of the 484C>T variant of FOLH1 (rs202676) with treatment was observed (P = .02), where only patients homozygous for the 484T allele demonstrated significantly greater benefit with active treatment (-0.59 change in SANS score per week; 95% CI, -0.99 to -0.18). In parallel, we observed an inverse relationship between red blood cell folate concentration at baseline and 484C allele load (P = .03), which persisted until 8 weeks of treatment. Change in positive and total symptoms did not differ between treatment groups.


Folate plus vitamin B12 supplementation can improve negative symptoms of schizophrenia, but treatment response is influenced by genetic variation in folate absorption. These findings support a personalized medicine approach for the treatment of negative symptoms.